Chemotherapy drugs associated with CIPN include thalidomide, the epothilones such as ixabepilone, the vinca alkaloids vincristine and vinblastine, the taxanes paclitaxel and docetaxel, the proteasome inhibitors such as bortezomib, and the platinum-based drugs cisplatin, oxaliplatin and carboplatin. and optic neuropathy, which is most common after several months of treatment and may also be irreversible. Although the mechanism of injury is still poorly understood, mitochondrial toxicity has been proposed as a cause; linezolid is toxic to mitochondria, probably because of the similarity between mitochondrial and bacterial ribosomes. Lactic acidosis, a potentially life-threatening buildup of lactic acid in the body, may also occur due to mitochondrial toxicity. Because of these long-term effects, the manufacturer recommends weekly complete blood counts during linezolid therapy to monitor for possible bone marrow suppression, and recommends that treatment last no more than 28 days. A more extensive monitoring protocol for early detection of toxicity in seriously ill patients receiving linezolid has been developed and proposed by a team of researchers in Melbourne, Australia. The protocol includes twice-weekly blood tests and liver function tests; measurement of serum lactate levels, for early detection of lactic acidosis; a review of all medications taken by the patient, interrupting the use of those that may interact with linezolid; and periodic eye and neurological exams in patients set to receive linezolid for longer than four weeks.The adverse effects of long-term linezolid therapy were first identified during postmarketing surveillance. Bone marrow suppression was not identified during Phase III trials, in which treatment did not exceed 21 days.
It can often be treated by drugs like corticosteroids or immunosuppressants. Inclusion body myositis is a slowly progressive disease that produces weakness of hand grip and straightening of the knees. No effective treatment is known. (M61) Myositis ossificans
(M62.89) Rhabdomyolysis and (R82.1) myoglobinuriasThe Food and Drug Administration is recommending that physicians restrict prescribing high-dose Simvastatin (Zocor, Merck) to patients, given an increased risk of muscle damage. The FDA drug safety communication stated that physicians should limit using the 80-mg dose unless the patient has already been taking the drug for 12 months and there is no evidence of myopathy. "Simvastatin 80 mg should not be started in new patients, including patients already taking lower doses of the drug," the agency states. Statin-associated autoimmune myopathy

Myocardium / cardio-myopathy
(I40) Acute myocarditis
(I41) Myocarditis in diseases classified elsewhere
(I42) Cardiomyopathy
(I42.0) Dilated cardiomyopathy
(I42.1) Obstructive hypertrophy cardiomyopathy
(I42.2) Other hypertrophic cardiomyopathy
(I42.3) Endomyocardial (eosinophilic) disease
Eosinophilic myocarditis
Endomyocardial (tropical) fibrosis
Löfflers endocarditis
(I42.4) Endocardial fibroelastosis
(I42.5) Other restrictive cardiomyopathy
(I42.6) Alcoholic cardiomyopathy
(I42.8) Other cardiomyopathies
Arrhythmogenic right ventricular dysplasia
(I43) Cardiomyopathy in diseases classified elsewhere

Differential diagnosis
At birth

None as systemic causes; mainly hereditaryOnset in childhood

Inflammatory myopathies – dermatomyositis, polymyositis (rarely)
Infectious myopathies
Endocrine and metabolic disorders – hypokalemia, hypocalcemia, hypercalcemiaOnset in adulthood
Inflammatory myopathies – polymyositis, dermatomyositis, inclusion body myositis, viral (HIV)
Infectious myopathies
Endocrine myopathies – thyroid, parathyroid, adrenal, pituitary disorders
Toxic myopathies – alcohol, corticosteroids, narcotics, colchicines, chloroquine
Critical illness myopathy
Metabolic myopathies
Paraneoplastic myopathy

Treatments
Because different types of myopathies are caused by many different pathways, there is no single treatment for myopathy. Treatments range from treatment of the symptoms to very specific cause-targeting treatments.